Trevi Therapeutics, Inc. TRVI

TRVI Company Overview

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious neurologically mediated conditions with significant unmet medical needs. The company’s primary focus is the development of nalbuphine extended-release formulations designed to treat chronic cough disorders and pruritic conditions. Trevi operates within the biotechnology and specialty pharmaceutical industries, with research and development activities centered on neuromodulation pathways involving opioid receptor activity.

The company’s lead product candidate is Haduvio™, an oral extended-release formulation of nalbuphine. Trevi has primarily concentrated development efforts on chronic cough indications, including refractory chronic cough and idiopathic pulmonary fibrosis-related chronic cough, while also evaluating applications in prurigo nodularis and other chronic pruritic conditions. Trevi’s strategic positioning is based on leveraging a mechanism that acts as both a kappa opioid receptor agonist and a mu opioid receptor antagonist, which the company believes may provide therapeutic benefit while limiting certain risks associated with traditional opioids. Trevi Therapeutics was founded in 2011 and is headquartered in Connecticut. The company became publicly traded on Nasdaq under the ticker TRVI following its merger with an existing public entity in 2019.